Retail Employees Superannuation Pty Ltd as trustee for Retail Employees Superannuation Trust Makes New Investment in IDEXX Laboratories, Inc. $IDXX

Retail Employees Superannuation Pty Ltd as trustee for Retail Employees Superannuation Trust acquired a new position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 8,692 shares of the company’s stock, valued at approximately $5,880,000. IDEXX Laboratories comprises about 1.6% of Retail Employees Superannuation Pty Ltd as trustee for Retail Employees Superannuation Trust’s holdings, making the stock its 25th biggest position.

A number of other large investors also recently bought and sold shares of the company. Huntington National Bank raised its position in IDEXX Laboratories by 1.8% during the 4th quarter. Huntington National Bank now owns 3,829 shares of the company’s stock worth $2,590,000 after buying an additional 69 shares during the last quarter. IPG Investment Advisors LLC purchased a new position in IDEXX Laboratories during the 4th quarter worth $1,499,000. Unified Investment Management purchased a new position in IDEXX Laboratories during the 4th quarter worth $203,000. Geode Capital Management LLC raised its position in IDEXX Laboratories by 3.5% during the 4th quarter. Geode Capital Management LLC now owns 2,583,939 shares of the company’s stock worth $1,749,380,000 after buying an additional 86,263 shares during the last quarter. Finally, Roundview Capital LLC purchased a new position in IDEXX Laboratories during the 4th quarter worth $294,000. Hedge funds and other institutional investors own 87.84% of the company’s stock.

IDEXX Laboratories Stock Performance

Shares of IDXX opened at $550.99 on Thursday. The company has a 50-day simple moving average of $565.23 and a 200-day simple moving average of $638.69. The company has a quick ratio of 0.82, a current ratio of 1.12 and a debt-to-equity ratio of 0.19. The company has a market capitalization of $43.46 billion, a PE ratio of 40.57, a P/E/G ratio of 3.24 and a beta of 1.58. IDEXX Laboratories, Inc. has a 52-week low of $504.56 and a 52-week high of $769.98.

IDEXX Laboratories (NASDAQ:IDXX) last announced its quarterly earnings results on Tuesday, May 5th. The company reported $3.47 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.41 by $0.06. The business had revenue of $1.14 billion during the quarter, compared to the consensus estimate of $1.12 billion. IDEXX Laboratories had a net margin of 24.63% and a return on equity of 70.87%. The business’s revenue was up 14.3% compared to the same quarter last year. During the same quarter last year, the firm posted $2.91 EPS. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. Equities research analysts predict that IDEXX Laboratories, Inc. will post 14.68 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other IDEXX Laboratories news, EVP Nimrata Hunt sold 1,758 shares of the firm’s stock in a transaction dated Tuesday, March 3rd. The shares were sold at an average price of $634.57, for a total transaction of $1,115,574.06. Following the completion of the transaction, the executive vice president directly owned 18,141 shares in the company, valued at approximately $11,511,734.37. This trade represents a 8.83% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Company insiders own 0.79% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have commented on IDXX. Barclays cut their price objective on shares of IDEXX Laboratories from $850.00 to $800.00 and set an “overweight” rating for the company in a research report on Thursday, February 5th. UBS Group cut their price target on shares of IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating for the company in a report on Tuesday, April 28th. Wall Street Zen downgraded shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Saturday, April 25th. BTIG Research cut their price target on shares of IDEXX Laboratories from $830.00 to $800.00 and set a “buy” rating for the company in a report on Tuesday, February 3rd. Finally, Stifel Nicolaus cut their price target on shares of IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating for the company in a report on Tuesday, March 31st. Seven research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $751.00.

About IDEXX Laboratories

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.